ERBB2 and non-small cell lung carcinoma: In non-small cell lung cancer cells, MET overexpression increased EGFR downstream signaling and the combined use of dual EGFR/HER2 and MET tyrosine kinase inhibitors resulted in a maximal growth inhibition [31].